期刊
HEALTH AFFAIRS
卷 26, 期 1, 页码 186-194出版社
PROJECT HOPE
DOI: 10.1377/hlthaff.26.1.186
关键词
-
资金
- AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010881] Funding Source: NIH RePORTER
- AHRQ HHS [2-R01-HS10881] Funding Source: Medline
Taken in combination, aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins (combination pharmacotherapy) greatly reduce cardiac events. These therapies are underused, even among patients with drug insurance. Out-of-pocket spending is a key barrier to adherence. We estimated the impact of providing combination pharmacotherapy without cost sharing (full coverage) to insured patients after a myocardial infarction (MI). Under base-case assumptions, compared to standard coverage, three years of full coverage will reduce mortality and reinfarction rates and will save $5,974 per patient. Our analysis suggests that covering combination therapy for such patients will save both lives and money.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据